Precision oral appliance therapy effective among 90% of moderate and 85% of severe OSA patients In an Intent-to-Treat analysis, precision OAT demonstrated twice the mean disease alleviation as ...

PLEASANTON, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced the presentation of ...

Median efficacy for Precision OAT in individuals with severe OSA was 59%, while that of Traditional OAT was 50%. At ATS 2023, further data were presented in the following poster: ...

After identifying anatomical risk factors for OSA, such as small upper airways, dentists can then refer at-risk patients to sleep medicine specialists for diagnostic testing, according to the report.

"ProSomnus Precision OAT devices help increase patient compliance and safety for Veterans living with Obstructive Sleep Apnea (OSA). I think it’s safe to say, no one enjoys sleeping with a CPAP.

89% of all patients and 98.5% of mild to moderate OSA patients were treated to an apnea-hypopnea index (AHI) of fewer than ten events per hour. 80% of severe OSA patients were treated to an AHI of ...

Results for treating Severe OSA patients with precision oral appliance therapy establish rationale for head-to-head clinical trial with hypoglossal nerve stimulation PLEASANTON, Calif., Aug. 23 ...

Median efficacy for Precision OAT in individuals with severe OSA was 59%, while that of Traditional OAT was 50%. At ATS 2023, further data were presented in the following poster: ...

This investigation is one of the first to demonstrate the efficacy of precision OAT, or any OSA treatment for that matter, using a risk-based (sleep apnea specific hypoxic burden “SASHB”) index.

This investigation is one of the first to demonstrate the efficacy of precision OAT, or any OSA treatment for that matter, using a risk-based (sleep apnea specific hypoxic burden “SASHB”) index.